Lipid-regulating properties of butyric acid and 4-phenylbutyric acid: Molecular mechanisms and therapeutic applications

Research output: Contribution to journalReview article

Abstract

In the past two decades, significant advances have been made in the etiology of lipid disorders. Concomitantly, the discovery of liporegulatory functions of certain short-chain fatty acids has generated interest in their clinical applications. In particular, butyric acid (BA) and its derivative, 4-phenylbutyric acid (PBA), which afford health benefits against lipid disorders while being generally well tolerated by animals and humans have been assessed clinically. This review examines the evidence from cell, animal and human studies pertaining to the lipid-regulating effects of BA and PBA, their molecular mechanisms and therapeutic potential. Collectively, the evidence supports the view that intakes of BA and PBA benefit lipid homeostasis across biological systems. We reviewed the evidence that BA and PBA downregulate de novo lipogenesis, ameliorate lipotoxicity, slow down atherosclerosis progression, and stimulate fatty acid β-oxidation. Central to their mode of action, BA appears to function as a histone deacetylase (HDAC) inhibitor while PBA acts as a chemical chaperone and/or a HDAC inhibitor. Areas of further inquiry include the effects of BA and PBA on adipogenesis, lipolysis and apolipoprotein metabolism.

Original languageEnglish (US)
Pages (from-to)116-131
Number of pages16
JournalPharmacological Research
Volume144
DOIs
StatePublished - Jun 2019

Fingerprint

Butyric Acid
Lipids
Acids
Histone Deacetylase Inhibitors
Therapeutics
Adipogenesis
Lipogenesis
Volatile Fatty Acids
Apolipoproteins
Lipolysis
Insurance Benefits
4-phenylbutyric acid
Atherosclerosis
Homeostasis
Fatty Acids
Down-Regulation

Keywords

  • Chemical chaperone
  • HDAC
  • Lipogenesis
  • Lipolysis
  • Lipoprotein

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{e17d27d58a804fe5ae30516397b18526,
title = "Lipid-regulating properties of butyric acid and 4-phenylbutyric acid: Molecular mechanisms and therapeutic applications",
abstract = "In the past two decades, significant advances have been made in the etiology of lipid disorders. Concomitantly, the discovery of liporegulatory functions of certain short-chain fatty acids has generated interest in their clinical applications. In particular, butyric acid (BA) and its derivative, 4-phenylbutyric acid (PBA), which afford health benefits against lipid disorders while being generally well tolerated by animals and humans have been assessed clinically. This review examines the evidence from cell, animal and human studies pertaining to the lipid-regulating effects of BA and PBA, their molecular mechanisms and therapeutic potential. Collectively, the evidence supports the view that intakes of BA and PBA benefit lipid homeostasis across biological systems. We reviewed the evidence that BA and PBA downregulate de novo lipogenesis, ameliorate lipotoxicity, slow down atherosclerosis progression, and stimulate fatty acid β-oxidation. Central to their mode of action, BA appears to function as a histone deacetylase (HDAC) inhibitor while PBA acts as a chemical chaperone and/or a HDAC inhibitor. Areas of further inquiry include the effects of BA and PBA on adipogenesis, lipolysis and apolipoprotein metabolism.",
keywords = "Chemical chaperone, HDAC, Lipogenesis, Lipolysis, Lipoprotein",
author = "Bo He and R{\'e}gis Moreau",
year = "2019",
month = "6",
doi = "10.1016/j.phrs.2019.04.002",
language = "English (US)",
volume = "144",
pages = "116--131",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Lipid-regulating properties of butyric acid and 4-phenylbutyric acid

T2 - Molecular mechanisms and therapeutic applications

AU - He, Bo

AU - Moreau, Régis

PY - 2019/6

Y1 - 2019/6

N2 - In the past two decades, significant advances have been made in the etiology of lipid disorders. Concomitantly, the discovery of liporegulatory functions of certain short-chain fatty acids has generated interest in their clinical applications. In particular, butyric acid (BA) and its derivative, 4-phenylbutyric acid (PBA), which afford health benefits against lipid disorders while being generally well tolerated by animals and humans have been assessed clinically. This review examines the evidence from cell, animal and human studies pertaining to the lipid-regulating effects of BA and PBA, their molecular mechanisms and therapeutic potential. Collectively, the evidence supports the view that intakes of BA and PBA benefit lipid homeostasis across biological systems. We reviewed the evidence that BA and PBA downregulate de novo lipogenesis, ameliorate lipotoxicity, slow down atherosclerosis progression, and stimulate fatty acid β-oxidation. Central to their mode of action, BA appears to function as a histone deacetylase (HDAC) inhibitor while PBA acts as a chemical chaperone and/or a HDAC inhibitor. Areas of further inquiry include the effects of BA and PBA on adipogenesis, lipolysis and apolipoprotein metabolism.

AB - In the past two decades, significant advances have been made in the etiology of lipid disorders. Concomitantly, the discovery of liporegulatory functions of certain short-chain fatty acids has generated interest in their clinical applications. In particular, butyric acid (BA) and its derivative, 4-phenylbutyric acid (PBA), which afford health benefits against lipid disorders while being generally well tolerated by animals and humans have been assessed clinically. This review examines the evidence from cell, animal and human studies pertaining to the lipid-regulating effects of BA and PBA, their molecular mechanisms and therapeutic potential. Collectively, the evidence supports the view that intakes of BA and PBA benefit lipid homeostasis across biological systems. We reviewed the evidence that BA and PBA downregulate de novo lipogenesis, ameliorate lipotoxicity, slow down atherosclerosis progression, and stimulate fatty acid β-oxidation. Central to their mode of action, BA appears to function as a histone deacetylase (HDAC) inhibitor while PBA acts as a chemical chaperone and/or a HDAC inhibitor. Areas of further inquiry include the effects of BA and PBA on adipogenesis, lipolysis and apolipoprotein metabolism.

KW - Chemical chaperone

KW - HDAC

KW - Lipogenesis

KW - Lipolysis

KW - Lipoprotein

UR - http://www.scopus.com/inward/record.url?scp=85064249672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064249672&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2019.04.002

DO - 10.1016/j.phrs.2019.04.002

M3 - Review article

C2 - 30954630

AN - SCOPUS:85064249672

VL - 144

SP - 116

EP - 131

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

ER -